Natera has announced it will report second quarter 2026 results on August 6, 2026, after the market close, followed by a conference call and webcast. The stock has delivered a 29.18% return over the past 90 days and a 98.96% total shareholder return over the past year, with shares recently trading at US$267.76. The most followed valuation narrative places fair value at about US$282.14 per share, suggesting the stock is roughly 5.1% undervalued, while a discounted cash flow model points to a much higher estimated value of around US$556.56 per share. Growth is being driven by increasing adoption of advanced molecular diagnostics, particularly in oncology and organ health, though risks remain if clinical trials disappoint or reimbursement policies tighten.
Natera IncEarnings date announcement and valuation analysis suggest undervaluation, with strong recent performance.